- FDA U-turn triggers crash: uniQure (NASDAQ: QURE) shares fell over 50% in one day after U.S. regulators said current clinical data for its experimental Huntington’s disease gene therapy is not adequate for approvalreuters.com. This reversal comes just weeks after uniQure’s trial results were hailed as “game-changing”1 .
- Wild price swing: QURE stock plummeted from about $68 to the low-$30s, erasing roughly half of its market value (now ~$2.1 B)stockanalysis.com. It hit an intraday low near $23 before partially rebounding to ~$34stockinvest.us, still down ~54% on the news2 .
- Surprise FDA setback: The FDA no longer agrees that uniQure’s Phase 1/2 data (with external control) can support a BLA (marketing application) under accelerated approvalreuters.com – a “drastic change” from prior guidance, uniQure’s CEO saidglobenewswire.com. The timeline for approval is now unclear, likely delaying any U.S. launch beyond 20263 .
- Analyst reactions: Experts call this a major regulatory setbackreuters.com. Guggenheim’s analyst noted the FDA now sees uniQure’s analysis as “post hoc” (not pre-specified)reuters.com, and another analyst warned new trials or data may be neededreuters.com. Some have cut price targets (e.g. one lowered from $76 to $53benzinga.com), though the pre-news consensus target was ~$68 with a Strong Buy rating4 .
- Investor sentiment & fallout: The shock has rattled biotech investors – uniQure’s stock had soared ~300% in September after positive trial datafiercebiotech.com, and now enthusiasm has flipped to disappointment. Shareholder rights law firms quickly launched investigations for potential securities fraud (citing the 57% one-day plunge)businesswire.combusinesswire.com, reflecting investor outrage.
- Technical picture: Technically, QURE is in free-fall territory. The gap-down left no clear support levels; shares traded in a wide ~$22–$36 range on the crash daystockinvest.us. Volume spiked to ~30 million shares (vs. ~1–2 million typical), indicating intense selling pressurestockinvest.us. The stock is now well below key moving averages (which sit around $52–$62)5
UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?
Stock Market Today
Stock Market Today 07.02.2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:46 AM EST Sensex and Nifty Bounce Back Amid IT Sector Weakness, Eyes on US-India Trade Deal February 7, 2026, 12:46 AM EST. India's Sensex rose 0.3% to 83,580.40 and Nifty gained 0.2% to 25,693.7 on Friday, recovering from early losses. The Nifty IT index dropped 1.5%, extending a weekly fall of 5%, pressured by a global tech sell-off linked to rising AI spending and competition. Foreign investors bought equities worth ₹1,951 crore, while domestic institutions sold ₹1,265 crore. The market is cautiously awaiting details of the US-India
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
